Biogen Digital Health

Our Portfolio

Our Digital Health Solutions

Our portfolio of digital health solutions includes initiatives across clinical development and real-world settings in various stages (development, validation, and in-market) and different therapeutic areas.

We focus on three main categories: digital health solutions, digital medicine solutions, and digital therapeutics.


In Dev., Validation

Digital Health

Digital health solutions include technologies, platforms, and systems that engage consumers for lifestyle, wellness, and health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations.

Stage:  In-Market

Digital care companion smartphone app to help people better live with MS

Cleo/Aby provides information, tips, symptom-tracking, reminders, and tailored programs for self-care with the goal of improving the daily lives of people living with MS and their caregivers.
Stage:  Validation

Remote exercise platform that offers at-home, tailored programs for people with neuromuscular diseases.

With, the physiotherapist team defines a tailored program adapted to the patient’s specific goals. The patient can then perform exercises from the comfort of their own home.

Stage: In-Market

Website for healthcare professionals to stay informed about the latest developments in neuroscience

Neurodiem is an independent information and education platform with scientifically validated content to help healthcare professionals remain at the forefront in neuroscience.
Neurodiem is available in 30 countries and nine languages. Over 120 pieces of content are published monthly.

Digital Medicine

Digital medicine solutions include evidence-based software and/or hardware products that measure and/or intervene in the service of human health (e.g., digital biomarkers and remote patient monitoring).

Stage:  In-Market

Generating research-grade data at real-world scale to unlock novel insights on MS disease and therapies

MS PATHS uses advanced technology to curate longitudinal, multi-dimensional patient data during routine visits (clinical, imaging, biosamples, etc.). It aims to improve patient outcomes and enable reverse translational research.

Stage:  In-Market

iPad-based cognitive assessment for people with multiple sclerosis

CogEval is an iPad-based assessment designed to evaluate cognitive function in-clinic for patients with multiple sclerosis.

Stage: In-Market

In-clinic standardized patient assessment device

Multiple Sclerosis Performance Test (MSPT) is an in-clinic assessment tool that aims to objectively quantify the major motor, visual, and cognitive systems, as well as quality of life and disease history for patients with MS. Healthcare providers (HCPs) can access patient results at the point of care.

Stage:  Development

Artificial intelligence for ARIA identification

FDA-listed AI algorithm that can be applied to any MRI image collected with a recommended protocol to help identify, quantify, and classify ARIA*. This could aid in clinical decisions and would be integrated into the neuro-radiology workflow.
*ARIA stands for Amyloid-Related Imaging Abnormalities, which patients on amyloid-lowering medications may experience.

Stage:  Development

Virtual study of mild cognitive impairment and brain health digital biomarkers

Virtual, observational study for adults aged 21–85 in the U.S. using an Apple Watch and iPhone. Investigates the use of active and passive data to develop digital biomarkers that could potentially aid in earlier detection of mild cognitive impairment, as well as identify changes in a person’s brain health.

Stage: Validation

Virtual reality (VR) solution to improve neuromuscular disease patients’ experience during medical procedures

Evidence-based Class I medical device that combines immersion through VR technology and medical hypnosis. Our ambition is to expand the program’s global footprint to cover 12 international markets by the end of 2023.

Stage:  Validation

Patient-centric digital biomarker platform to assess neurological functions remotely for more precise, frequent measurement of disease evolution

Konectom seeks to support real-world evidence and enable R&D decisions with sensitive and predictive measures of disease progression. It uses scientifically validated active and passive assessment modules leveraging smartphone sensors to assess cognition, fine motor control, mobility, quality of life, and other domains in-clinic or remotely.

MS Lesion Analyzer (In collaboration with Therapanacea)
Stage:  Development

Classifier leveraging machine learning to potentially predict lesion age and serve as a prognostic tool for future disease activity

MS Lesion Analyzer aims to help unlock insights about underlying disease processes previously unseen to the human eye. This solution is intended to enable personalized and earlier treatment decisions in MS.


Digital Therapeutics

Digital therapeutics (DTx) aim to deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease.

MR-004 (In collaboration with MedRhythms)
Stage:  Development

Walking disability, a common symptom of MS, significantly decreases independence, reduces quality of life, and increases falls. Research has shown that music-based rhythmic auditory stimulation (RAS) can improve walking speed, stride length, and symmetry, and even reduce falls.

MR-004 combines sensors, software, and music to target neural circuitry. The study plans to test a course of therapy of three 30-minute sessions per week for three months.



Biogen Digital Health

Digital vision: a conversation with Martin Dubuc


Biogen Digital Health

Seizing the inflection point - The potential for AI to advance personalized healthcare


Biogen Digital Health

What clinical trials of the future might look like

See All